web analytics
19.5 C
Munich
Friday, June 18, 2021

Enzolytics Inc. ENZC BioClonetics A Perfect Merger & Major League Runner

Enzolytics Inc. ENZC: is making a highly explosive move up the charts recently surpassing $0.50 per share and regularly topping $25 million USD per day in dollar volume ENZC has transformed into a major league runner in small caps. Enzolytics and its new subsidiary BioClonetics own licensing rights of the Irreversible Pepsin Fraction peptide molecule for the treatment of HIV/AIDS a market expected to be worth $30 billion plus by 2025. The Company produces targeted (nontoxic) monoclonal antibodies and is now advancing two separate but complementary therapy platforms for treating infectious diseases, targeting HIV and the CoronaVirus. 

Enzolytics has attracted a major league level management team behind it and has expanded its lab capabilities on the Texas A&M University campus at the Institute for Pre-clinical Studies, where it is producing both addition monoclonal antibodies against HIV and the against covid-19. This expansion allows Enzolytics to complete the production of monoclonal antibodies against both the HIV virus and the coronavirus and collaborate with the biopharma experts on the campus. Microcapdaily first reported on ENZC the day after the merger was announced in our aritcle: “BioClonetics LOI Sparks Enzolytics Inc (OTCMKTS: ENZC)” on September 16 when ENZC was trading for well under $0.01 

Enzolytics, Inc.; BioClonetics; the Perfect Merger: Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Enzolytics’ flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. 

BioClonetics Immunotherapeutics, Inc., a wholly owned subsidiary of Enzolytics, is a Dallas and College Station, Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for producing fully human monoclonal antibodies may be used to produce therapeutics treatments for many infectious diseases including the Coronavirus. 

The newly combined Companies are led by CEO and majority shareholder Charles S. Cotropia, a well-known intellectual property attorney who has litigated over 200 patents in his career and served as lead counsel in several landmark patent disputes litigated in Federal Courts and the US Patent and Trademark Office. Mr. Cotropia founded BioCLonetics along with his brother Dr. Joseph Cotropia, MD, who pioneered BioCLonetics proprietary method for creating human cell lines that produce human antibodies directed against many infectious diseases. One cell (designated as CLONE 3) has been demonstrated in multiple tests and 5 Independent studies to neutralize the HIV virus in 98% of all known varieties world-wide. 

ENZC has been rapidly building up an intellectual property portfolio filing numerous patents last year. Most recently, last month, the Company reported it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent application for “Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor – Pharmaceutical Composition for Treatment.”  

We reported on the ENZC BioClonetics merger from the beginning staring when ENZC was well under $0.01 with our September 16, 2020 article titled: BioClonetics LOI Sparks Enzolytics Inc (OTCMKTS: ENZC). CEO Charles Cotropia described the merger in his recent year end address: “On September 15, 2020, Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. (“BCLS” or “BioClonetics”) entered into a non-binding letter of intent to combine the two entities and pursue our joint mission to create therapeutics that are effective and affordable for the treatment of some of the most infectious and deadly diseases in the world, including HIV and the Coronavirus. This goal has as its foundation several components – (1) our patented anti-HIV therapeutics that have been successfully clinically tested, (2) our anti-HIV monoclonal parent antibody previously tested in vitro, demonstrating neutralization of over 95% of the HIV isolates against which it was tested and (3) our proprietary methodology for producing fully human monoclonal antibodies which is being used to produce additional anti-HIV monoclonal antibodies targeting additional immutable sites on the HIV virus as well as multiple anti-CoronaVirus monoclonal antibodies for use as a therapeutic against the SARS-CoV-2 virus.” 

To Find out the inside Scoop on ENZC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ENZC

ENZC – Monoclonal Antibodies: Several weeks ago the FDA authorized the use of monoclonal antibodies for Covid-19 treatments. It said: “Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses. Casirivimab and imdevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells.  While vaccines can stop people from contracting Covid and becoming seriously ill, treatments will still be needed for those who already have it. 

On February 1 ENZC announced it has identified seven additional conserved, expectedly immutable sites on the HIV virus against which it plans to produce targeted anti-HIV monoclonal antibodies. The Company’s primary anti-HIV monoclonal antibody targets one conserved site on the HIV virus, which site is 98% conserved (either directly or by way of conservative amino acid substitutions) over all 87,336 HIV isolates which have now been curated (analyzed) by the Company using Artificial Intelligence (AI). Additional conserved target sites (some with 98% conserved sequences) have now been identified against which fully human anti-HIV monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University’s Institute for Preclinical Studies. The significance of producing multiple monoclonal antibodies targeting multiple conserved sites is recognized by experts as a critical approach to effective therapy. This allows the administration of a “cocktail” of antibodies, all targeting conserved and expectedly immutable sites. 

Additionally, the Company’s Genetics and Molecular Biology data science team is now screening (using computer analysis/Artificial Intelligence [AI]) more than 275,000 CoronaVirus isolates now known, to also identify conserved sites which expectedly are immutable. From this information, anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies will be produced. The significance of producing monoclonal antibodies against conserved target sites on targeted viruses is made evident by the mutant strains of the CoronaVirus currently surfacing in the U.S, South Africa, Brazil, United Kingdom and around the world. The same virus mutation exists with HIV, as well as other well-known viruses. As a virus mutates, a therapeutic becomes ineffective when it neutralizes by attacking a site that changes. By targeting an immutable site, a therapeutic is not affected by the mutation. This is well understood by the necessity to produce a new flu vaccine with each flu season, namely because the flu virus mutates. Producing therapeutics that target a conserved site on viruses makes possible the production of a therapeutic that is not rendered ineffective by virus mutation, and therefore can be applied successfully both universally around the world and durably over time. 

The Company is also applying Artificial Intelligence [AI] to scan the hundreds of thousands of isolates that exist in 14 other prevalent viruses, ranging from influenza to Rabies to Ebola. Using the Company’s proprietary technique for producing fully human monoclonal antibodies directed against these infectious diseases, the Company will produce multiple neutralizing monoclonal antibodies against these viruses. The significance of this approach is well recognized by experts in virology due to the ability of all viruses to mutate and render ineffective initially developed therapeutics. 

CEO Charles Cotropia stated, “The Company is making significant progress on both of its therapeutic platforms: first, on the identification of prime target sites on both the CoronaVirus and the HIV virus and the creation of neutralizing antibodies directed against these sites, and second, on advancing its ITV-1 peptide therapeutic for patient application in the EU.” 

For more on ENZC Subscribe Right Now!

ENZC is making a highly explosive move up the charts recently surpassing $0.50 per share and regularly topping $25 million USD per day in dollar volume ENZC has transformed into a major league runner in small caps. Enzolytics and its new subsidiary BioClonetics own licensing rights of the Irreversible Pepsin Fraction peptide molecule for the treatment of HIV/AIDS a market expected to be worth $30 billion plus by 2025. The Company produces targeted (nontoxic) monoclonal antibodies and is now advancing two separate but complementary therapy platforms for treating infectious diseases, targeting HIV and the CoronaVirus. Enzolytics has attracted a major league level management team behind it and has expanded its lab capabilities on the Texas A&M University campus at the Institute for Pre-clinical Studies, where it is producing both addition monoclonal antibodies against HIV and the against covid-19. This expansion allows Enzolytics to complete the production of monoclonal antibodies against both the HIV virus and the coronavirus and collaborate with the biopharma experts on the campus. Microcapdaily first reported on ENZC the day after the merger was announced in our aritcle: BioClonetics LOI Sparks Enzolytics Inc (OTCMKTS: ENZC)” on September 16 when ENZC was trading for well under $0.01. We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENZC.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.